Výsledky vyhledávání - "Joseph Sliman"

Akademický článek

Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.

Autor: Elissa Malkin, Ram Yogev, Nazha Abughali, Joseph Sliman, C Kathy Wang, Fengrong Zuo, Chin-Fen Yang, Mark Eickhoff, Mark T Esser, Roderick S Tang, Filip Dubovsky

Publikováno v: PLoS ONE, Vol 8, Iss 10, p e77104 (2013)

Despite substantial morbidity associated with respiratory syncytial virus (RSV) infection, there is no licensed vaccine. MEDI-559 is a live attenuated intranasal vaccine candidate being developed for prevention of lower respiratory illness due to RSV

Externí odkaz: https://doaj.org/article/51acecd6d9ea429382eebdb8ed9cf25a

Zobrazit plný text záznamu

Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection

Autor: Steven Hubert, John F. Kokai-Kun, Giovanni Widmer, Annie Jones, Todd Parsley, Nur A. Hasan, Sheila Connelly, Perrti Koski, J. Andrew Bristol, Michael Kaleko, Saul Tzipori, Poorani Subramanian, Joseph Sliman

Publikováno v: Anaerobe. 41:58-67

The gut microbiome, composed of the microflora that inhabit the gastrointestinal tract and their genomes, make up a complex ecosystem that can be disrupted by antibiotic use. The ensuing dysbiosis is conducive to the emergence of opportunistic pathog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcd00bc23048fef79afda3d09e5e11d1

Zobrazit plný text záznamu

Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies

Autor: J. Andrew Bristol, Heidi Whalen, John F. Kokai-Kun, Joseph Sliman, Kenneth C. Lasseter, Olivia Coughlin, Tracey Roberts, Steven Hubert, Barbara Valero Lopez, James Longstreth

Publikováno v: Clinical Drug Investigation. 36:725-734

SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous β-lactam antibiotics like cephalosporins. SYN-004 is intended to degrade residual antibiotics excreted into the intestine as a result o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1f60974d01086422b6d69cce43c547
https://doi.org/10.1007/s40261-016-0420-0

Zobrazit plný text záznamu

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

Autor: Vincent J. Wacher, Tracey M. Roberts, Olivia Coughlin, Heidi Whalen, John F. Kokai-Kun, Joseph Sliman, Ralph Stevenson, Chenxiong (Charles) Le

Publikováno v: The Lancet. Infectious diseases. 19(5)

Infections with Clostridium difficile are a health threat, yet no products are currently licensed for prevention of primary C difficile infections. Intravenous β-lactam antibiotics are considered to confer a high risk of C difficile infection becaus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6337d9ea89986147a7e037836d826697
https://pubmed.ncbi.nlm.nih.gov/30885590

Zobrazit plný text záznamu

SYN-004 (Ribaxamase), an Orally Administered β-Lactamase for Prevention of Clostridium Difficile Infection in Patients Treated with Intravenous β-Lactam Antibiotics: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study

Autor: John F. Kokai-Kun, Tracey M. Roberts, Ralph Stevenson, Joseph Sliman, Vincent J. Wacher, Heidi Whalen, Olivia Coughlin, Chenxiong (Charles) Le

Publikováno v: SSRN Electronic Journal.

Background: Clostridium difficile infection (CDI) is an urgent public health threat, yet there is no product currently licensed for its prevention. The use of intravenous β-lactam antibiotics are considered high risk for the development of CDI due t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59055f69e51c731ca0c65a13a3d42c48
https://doi.org/10.2139/ssrn.3234882

Zobrazit plný text záznamu

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

Autor: Eric Sicard, Heidi Whalen, Christian Carter, Joseph Sliman, John F. Kokai-Kun, Tracey Roberts, Marijke H. Adams, Marianne Rufiange, Olivia Coughlin, Richard N. Fedorak, James Longstreth

Publikováno v: Antimicrobial Agents and Chemotherapy

SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics, including most penicillins and cephalosporins. Ribaxamase's anticipated mechanism of action is to degrade excess β-lactam

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::701f2262cc280a874750e3fedaefde12
https://doi.org/10.1128/aac.02197-16

Zobrazit plný text záznamu

1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance

Autor: Julia L. Cope, John F. Kokai-Kun, Charles Le, Kenneth Trout, Joseph Sliman

Publikováno v: Open Forum Infectious Diseases

Background When β-lactam antibiotics are administered intravenously, a significant portion of each dose can be excreted through the bile into the intestine. This excess antibiotic disrupts the balance of the gut microbiome making the recipient more

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ccffeff6fa9a22ace1dd172f75f2fe7
https://doi.org/10.1093/ofid/ofy210.1169

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání